Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United States in October 2019. Beovu offers the potential for dosing once every 12 weeks immediately after the first three monthly doses, giving the product a dosing advantage over Lucentis and Eylea in its product labeling. However, a safety alert on Beovu from the American Society of Retinal Specialists in February 2020 and a subsequent safety review by Novartis resulted in Beovu’s prescribing information being updated in June 2020 to include a warning of retinal vasculitis and/or retinal vascular occlusion with Beovu injections, a warning that is absent from the labels of Eylea and Lucentis. This report provides a snapshot of Beovu’s performance based on physician responses nine months after its launch, including a comparison with survey data at three months postlaunch, before the safety issues with Beovu had emerged.

QUESTIONS ANSWERED

  • What are the awareness of, familiarity with, and perceptions related to Beovu among U.S. ophthalmologists / retinal specialists nine months after launch?
  • Is Beovu being prescribed to treatment-naive patients or as a switch therapy? What are the reasons for prescribing Beovu for wet AMD, and how satisfied are prescribers with the product
  • What are the main obstacles holding physicians back from administering Beovu to more of their wet AMD patients? Why have some physicians not yet used Beovu for wet AMD?

CONTENT HIGHLIGHTS

Geography: United States

Primary Research: Survey of 77 U.S. ophthalmologists / retinal specialists in July 2020

Key metrics included: Unaided and aided awareness of Beovu; familiarity with and impressions of Beovu; prescriber and nonprescriber profiles; willingness to prescribe Beovu; performance of Beovu on key attributes; sales representative visit frequency, reach, and effectiveness

PRODUCT DESCRIPTION

DRG’s Special Topics reports assess key trends in dynamic disease areas. Here we provide a snapshot of Beovu’s performance at nine months postlaunch in the U.S. wet AMD market. Specifically, we assess U.S. physicians’ awareness, perceptions, and use of Beovu, as well as Beovu’s current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts by Novartis, prescriber and nonprescriber profiles, and a comparison with survey data collected at three months postlaunch of Beovu.

Table of contents

  • Dry And Wet Age-Related Macular Degeneration - Special Topics - Dry And Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch For Wet AMD | US | 2020

Author(s): Emma McFadden, PhD; Emma McFadden, PhD

Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.

 

Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.

 


Related Reports

Dry And Wet Age-Related Macular Degeneration - Special Topics - Special Topics - Beovu - Three Months Postlaunch For Wet AMD (US)

Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment...

View Details

Dry And Wet Age-Related Macular Degeneration - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key 

View Details

Diabetic Macular Edema / Diabetic Retinopathy - Access & Reimbursement - Detailed, Expanded Analysis: Special Focus On Retinal Therapies: US Payer Management Of The Medical Benefit

As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to imp...

View Details